Accentia Biopharmaceuticals (ABPI) Subsidiary Receives Rare Disease Designation in Europe
More News related to ABPI
- Accentia Biopharmaceuticals (ABPI) Reports Q3 Loss of $0.25
- Accentia Biopharmaceuticals (ABPI) Agrees to $8.5M Private Placement to Fund SinuNase(TM) and Revimmune(TM) Strategies
- Unusual 11 Mid-Day Movers 6/11: ABPI, KMGB, FCN, AGU Higher; CENT, FED, SNIC, MTG Lower
- Accentia Biopharmaceuticals (ABPI) Announces SinuNase Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant
- Pre-Open Movers 4/17: FUQI Intl (FUQI) Higher on Raised Guidance, Nokia (NOK) Lower on Results/Outlook
More News related to BVTI
- Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter
- Unusual 11 Mid-Day Movers 6/11: ABPI, KMGB, FCN, AGU Higher; CENT, FED, SNIC, MTG Lower
- Accentia Biopharmaceuticals (ABPI) Subsidiary Receives Rare Disease Designation in Europe
- Accentia Biopharma (ABPI) Subsidiary, Biovest International (BVTI), Receives Positive Opinion for BiovaxID
- Accentia Biopharmaceuticals (ABPI) Subsidiary Biovest (BVTI) Receives FDA Fast Track Status For BiovaxID
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) said majority-owned subsidiary, Biovest International, Inc. (OTCBB: BVTI), has received notification from the Commission of the European Union on its acceptance of Biovest's BiovaxID therapy for Follicular Lymphoma for entry into the European Community's Drug Register for Rare Diseases.
This acceptance follows the previously announced recommendation by the Committee on Orphan Medical Products of the European Medicines Agency that BiovaxID be granted designation as a treatment for a rare disease
Related Categories
Corporate NewsStocks Mentioned
+0.00
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
